Key facts
- It has raised $730K; the latest was Early Stage VC ($730K) in Feb 2026.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Nanyu Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Nanyu Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nanyu Biotechnology
Manufacturer of advanced biopharmaceutical technologies intended to drive innovation in regenerative medicine and drug development. The company offers CAR-T and CAR-NK therapies, induced pluripotent stem cells, mesenchymal stem cells, and ultra-pure exosomes, enabling healthcare institutions and research organizations to accelerate therapeutic breakthroughs and enhance patient care.
- Sector
- Healthcare
- HQ
- Bangbu, China
- Founded
- 2023
- Ownership
- Privately Held (backing)
Nanyu Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nanyu Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nanyu Biotechnology in its N-PORT filings yet. We sweep new filings monthly.